Measuring Success

Warren Casey, PhD, DABT
Director, NICEATM
NTP Interagency Center for the Evaluation of Alternative Toxicological Methods

SACATM Meeting
September 18-19, 2017
All stakeholders should endeavor to identify appropriate metrics for prioritizing activities, monitoring progress, and measuring success.

- A challenge faced by all 3Rs efforts, including those conducted internationally, is determining the actual impact on the stated objective, whether it be reducing animal numbers or improving human relevance. The difficulty of measuring the impact on animal usage, in particular, is exacerbated in the United States due to limitations imposed by the Animal Welfare Act.

- Despite these difficulties, agency-specific mechanisms often exist that can be used to estimate the impact of a given activity, such as tracking the number of waivers granted for a particular animal test.

- In order to assess the impact of this national strategy, effective mechanisms need to be created to track progress and identify objective criteria for measuring success.
Common Approaches

• # animals used by industry

• # animals used for tests submitted to agencies

• # methods approved
US legal requirements for documenting animal use by species, number and test type

**Animal Welfare Act** (AWA, 7 U.S.C. 2131)

- Covers all animal species *with the exception of rats, mice, and birds*, which are not considered animals for the purposes of the Act. Rats and mice are the species most commonly used for toxicity testing. USDA Animal and Plant Health Inspection Service (APHIS) is responsible for the enforcement of the AWA.

- AWA requires reporting use of regulated species (i.e., not rats, mice) be reported by pain/distress category, but not by test type.
US legal requirements for documenting animal use by species, number and test type

**Animal Welfare Act** (AWA, 7 U.S.C. 2131)

- Covers all animal species *with the exception of rats, mice, and birds*, which are not considered animals for the purposes of the Act. Rats and mice are the species most commonly used for toxicity testing. USDA Animal and Plant Health Inspection Service (APHIS) is responsible for the enforcement of the AWA.

- AWA requires reporting use of regulated species (i.e., not rats, mice) be reported by pain/distress category, but not by test type.

**PHS Policy on Humane Care and Use of Laboratory Animals**

- Covers any research or testing on vertebrate animals (*including mice and rats*) conducted at facilities that receive PHS funding and compliance is monitored by NIH Office of Laboratory Animal Welfare (OLAW).

- OLAW requires annual reporting of average daily census of each species held at a facility, but these numbers do not reflect the purpose or actual numbers used for testing (i.e. numbers are estimates and include breeding colonies).
• Rats and mice account for ~90% of animals used for toxicological testing

• In the United States, there is no legal requirement to report the number of rats and mice use in toxicological testing

• There is no legal requirement to report the type of test conducted on any animal species.
• Regulatory agencies have vastly different reporting requirements and legal restrictions related to the submission and sharing of data from animal tests.
• Regulatory agencies have vastly different reporting requirements and legal restrictions related to the submission and sharing of data from animal tests.

• Animal data for products that fail during development are not generally submitted.
Challenges

• Would require significant resources from both agencies and industry

• Unlikely to yield information that is timely or actionable

• Animal use may fluctuate based on situational need (i.e., DOD), and therefore does not allow for an accurate comparison over time.

• Lack of international harmonization will result in continued use of animal testing even when approved alternatives exist.
How can we measure success?
### EPA Office of Pesticide Programs From Dec, 2011 to January, 2017

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Total # of Requests</th>
<th>Waivers Granted</th>
<th>Required Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhalation</td>
<td>288</td>
<td>222</td>
<td>66</td>
</tr>
<tr>
<td>Neurotoxicity</td>
<td>186</td>
<td>163.5</td>
<td>22.5</td>
</tr>
<tr>
<td>Dermal</td>
<td>57</td>
<td>50</td>
<td>7</td>
</tr>
<tr>
<td>Developmental</td>
<td>48</td>
<td>39</td>
<td>9</td>
</tr>
<tr>
<td>DNT</td>
<td>18</td>
<td>15</td>
<td>3</td>
</tr>
<tr>
<td>Subchronic Dog</td>
<td>14</td>
<td>11</td>
<td>3</td>
</tr>
<tr>
<td>Reproductive</td>
<td>38</td>
<td>32</td>
<td>6</td>
</tr>
<tr>
<td>Immunotoxicity</td>
<td>223</td>
<td>207</td>
<td>16</td>
</tr>
<tr>
<td>Chronic/ Carcinogenicity</td>
<td>28</td>
<td>24</td>
<td>4</td>
</tr>
<tr>
<td>Subchronic Rat</td>
<td>12</td>
<td>10</td>
<td>2</td>
</tr>
</tbody>
</table>
# Submitted Acute 6-Pack Studies

<table>
<thead>
<tr>
<th></th>
<th>Guideline</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute oral</td>
<td>870.1100</td>
<td>324</td>
<td>248</td>
<td>328</td>
<td>268</td>
</tr>
<tr>
<td>Acute dermal</td>
<td>870.1200</td>
<td>292</td>
<td>257</td>
<td>313</td>
<td>255</td>
</tr>
<tr>
<td>Acute inhalation</td>
<td>870.1300</td>
<td>264</td>
<td>217</td>
<td>248</td>
<td>254</td>
</tr>
<tr>
<td>Eye irritation</td>
<td>870.2400</td>
<td>291</td>
<td>261</td>
<td>273</td>
<td>251</td>
</tr>
<tr>
<td>Skin irritation</td>
<td>870.2500</td>
<td>270</td>
<td>254</td>
<td>268</td>
<td>258</td>
</tr>
<tr>
<td>Skin sensitization</td>
<td>870.2600</td>
<td>247</td>
<td>237</td>
<td>262</td>
<td>267</td>
</tr>
</tbody>
</table>
Why can’t we just count the number of new methods?

- Is it better to have 100 new methods that are seldom used and have little impact on animal usage, or one method that has a significant impact?
Why can’t we just count the number of new methods?

- Is it better to have 100 new methods that are seldom used and have little impact on animal usage, or one method that has a significant impact?
  - Murine local lymph node assay (LLNA) for skin sensitization (reduction and refinement of animal use)
Why can’t we just count the number of new methods?

• Is it better to have 100 new methods that are seldom used and have little impact on animal usage, or one method that has a significant impact?

  – Murine local lymph node assay (LLNA) for skin sensitization (reduction and refinement of animal use)
  
  – Reduced LLNA protocol (requires 40% fewer animals by using only the high dose group)
Why can’t we just count the number of new methods?

• Is it better to have 100 new methods that are seldom used and have little impact on animal usage, or one method that has a significant impact?

  – Murine local lymph node assay (LLNA) for skin sensitization (reduction and refinement of animal use)

  – Reduced LLNA protocol (requires 40% fewer animals by using only the high dose group)

  – LLNA: DA for skin sensitization testing (a nonradioisotopic LLNA test method)
Why can’t we just count the number of new methods?

• Is it better to have 100 new methods that are seldom used and have little impact on animal usage, or one method that has a significant impact?
  
  – Murine local lymph node assay (LLNA) for skin sensitization (reduction and refinement of animal use)
  
  – Reduced LLNA protocol (requires 40% fewer animals by using only the high dose group)
  
  – LLNA: DA for skin sensitization testing (a nonradioisotopic LLNA test method)
  
  – LLNA: BrdU-ELISA for skin sensitization testing (a nonradioisotopic LLNA test method)
Why can’t we just count the number of new methods?

• Is it better to have 100 new methods that are seldom used and have little impact on animal usage, or one method that has a significant impact?

  – Murine local lymph node assay (LLNA) for skin sensitization (reduction and refinement of animal use)
  – Reduced LLNA protocol (requires 40% fewer animals by using only the high dose group)
  – LLNA: DA for skin sensitization testing (a nonradioisotopic LLNA test method)
  – LLNA: BrdU-ELISA for skin sensitization testing (a nonradioisotopic LLNA test method)
  – LLNA for potency categorization of skin sensitizers (refinement and reduction of animal use)
Opportunities
Opportunities

• Use animal numbers where available and appropriate: i.e., Leptospirosis
Opportunities

- Use animal numbers where available and appropriate: i.e., Leptospirosis
- Annual use of EPA Waivers
Opportunities

• Use animal numbers where available and appropriate: i.e., Leptospirosis

• Annual use of EPA Waivers

• Target zero animal use - in many cases, there are tractable targets for the complete replacement of animal testing (i.e., biologics).
Opportunities

- Use animal numbers where available and appropriate: i.e., Leptospirosis
- Annual use of EPA Waivers
- Target zero animal use - in many cases, there are tractable targets for the complete replacement of animal testing (i.e., biologics).
- Standardized electronic reporting could enable the future application of analytics